3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
64
Cisplatin
44
Cetuximab
26
Carboplatin
25
Paclitaxel
19
Magnetic Resonance Spectroscopy
19
Radiotherapy, Intensity-Modulated
17
Nivolumab
17
Radiotherapy
16
Specimen Handling
15
Docetaxel
14
Platinum
13
1,2-diaminocyclohexaneplatinum II citrate
12
Taxes
8
Fluorouracil
8
Biopsy
8
atezolizumab
6
Radiation
6
(225)Ac-DOTA-c(RGDyK)
6
dostarlimab
5
cemiplimab
5
Ipilimumab
5
Immunoglobulin G
5
Cyclophosphamide
5
Surgical Procedures, Operative
4
Standard of Care
4
Immune Checkpoint Inhibitors
4
Disulfides
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled